Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.12.01.518149

SARS-CoV-2 mRNA vaccine is re-adenylated in vivo, enhancing antigen production and immune response

Abstract

Though mRNA vaccines against COVID-19 have revolutionized vaccinology and have been administered in billions of doses, we know incredibly little about how mRNA vaccines are metabolized in vivo. Here we implemented enhanced nanopore Direct RNA sequencing (eDRS), to enable the analysis of single Modernas mRNA-1273 molecules, giving in vivo information about the sequence and poly(A) tails. We show that mRNA-1273, with all uridines replaced by N1-methylpseudouridine (m{Psi}), is terminated by a long poly(A) tail (~100 nucleotides) followed by an m{Psi}Cm{Psi}AG sequence. In model cell lines, mRNA-1273 is swiftly degraded in a process initiated by the removal of m{Psi}Cm{Psi}AG, followed by CCR4-NOT-mediated deadenylation. In contrast, intramuscularly inoculated mRNA-1273 undergoes more complex modifications. Notably, mRNA-1273 molecules are re-adenylated after m{Psi}Cm{Psi}AG removal. Detailed analysis of immune cells involved in antigen production revealed that in macrophages, after m{Psi}Cm{Psi}AG removal, vaccine mRNA is very efficiently re-adenylated, and poly(A) tails can reach up to 200A. In contrast, in dendritic cells, vaccine mRNA undergoes slow deadenylation-dependent decay. We further demonstrate that enhancement of mRNA stability in macrophages is mediated by TENT5 poly(A) polymerases, whose expression is induced by the vaccine itself. Lack of TENT5-mediated re-adenylation results in lower antigen production and severely compromises specific immunoglobulin production following vaccination. Together, our findings provide an unexpected principle for the high efficacy of mRNA vaccines and open new possibilities for their improvement. They also emphasize that, in addition to targeting a protein of interest, the design of mRNA therapeutics should be customized to its cellular destination.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Krawczyk, P. S., Gewartowska, O., Mazur, M., Orzel, W., Matylla-Kulinska, K., Jelen, S., Turowski, P., Spiewla, T., Tarkowski, B., Tudek, A., Brouze, A., Wesolowska, A., Nowis, D., Golab, J., Kowalska, J., Jemielity, J., Dziembowski, A., Mroczek, S.. 2022-12-01. SARS-CoV-2 mRNA vaccine is re-adenylated in vivo, enhancing antigen production and immune response. https://doi.org/10.1101/2022.12.01.518149

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies

Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.

immunology↗

Development of lentiviral vectors specifically targeting CD4+ cells

Because of their central role in immunity, CD4+ T cells are a key target for genetic modification in many therapeutic applications, and lentiviral vectors with a VSV-G envelope are often used for this engineering. However, due to their broad tropism, these vectors are inadequate for cell-targeted in vivo gene delivery. Here, we explored using HIV-1 Env, which has a natural tropism towards these cells, as an alternative. We describe a three-plasmid vector production system to incorporate a panel of CCR5- or CXCR4-tropic Envs. These Env proteins are expressed from pCAG, a plasmid with reduced HIV-1 elements. We identify HIV-1 Env-incorporating vectors that can be produced with sufficient titres to specifically transduce primary CD4+ T cells in the context of in vitro mixed populations of peripheral blood mononuclear cells. We show efficient and specific transduction of HIV-1 Env vectors delivering an anti-CD19 chimeric antigen receptor (CAR). We demonstrate functional activity of the generated CD4+ CAR T cells, leading to the targeted killing of B cells in those mixed cell populations. Our methodology enables the production of HIV-1 Env-incorporating lentiviral vectors with defined CD4 targeted delivery, opening avenues for direct in vivo CAR T cell generation.

immunology↗

A Senescence-Like State is associated with the Immunosuppressive Phenotype of Tumor-Infiltrating Regulatory T Cells

Regulatory T (Treg) cells are essential mediators of immune suppression within the tumor microenvironment (TME) and represent a major barrier to effective anti-tumor immunity and to therapeutic efficacy of immune checkpoint inhibitors (ICIs). Cellular senescence is traditionally characterized by stable cell-cycle arrest accompanied by distinct molecular and functional changes, yet whether tumor-infiltrating (TI) Treg cells acquire senescence-associated features and how these features influence their immunosuppressive activity remain poorly understood. Here, we demonstrate that TI-Treg cells exhibit both apoptosis- and senescence-associated phenotype while retaining, and in some cases likely enhancing, their immunosuppressive capacity. Compared with peripheral Treg cells, some TI-Treg cells from solid cancers display elevated canonical senescence-associated markers, including p16 and p21, DNA damage response pathways, senescence-associated secretory phenotype (SASP) and anti-apoptotic BCL-2 family genes, as well as activation of secretion associated beta-galactosidase (SA-beta-Gal). Though physiological Treg senescence leads to diminished immune suppression, TI-Treg cells paradoxically maintain the expression of key immunosuppressive molecules. These findings identify a previously unrecognized senescence-like state in TI-Treg cells that is functionally distinct from the loss of fitness typically associated with senescence in other cell types or aging-associated Treg senescence. Our study establishes senescence-associated reprogramming as a defining feature of TI-Treg cells and highlights the senescence-like state of Treg cells as a potential therapeutic target for selectively disrupting tumor immune suppression while preserving systemic immune homeostasis.

immunology↗